CCT6A may act as a potential biomarker reflecting tumor size, lymphatic metastasis, FIGO stage, and prognosis in cervical cancer patients.
Adult
Biomarkers, Tumor
/ genetics
Chaperonin Containing TCP-1
/ genetics
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Lymphatic Metastasis
/ genetics
Middle Aged
Prognosis
Proportional Hazards Models
Reverse Transcriptase Polymerase Chain Reaction
Uterine Cervical Neoplasms
/ genetics
CCT6A
cervical cancer
disease-free survival
overall survival
tumor characteristics
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
01
04
2021
received:
02
03
2021
accepted:
03
04
2021
pubmed:
2
7
2021
medline:
11
1
2022
entrez:
1
7
2021
Statut:
ppublish
Résumé
Chaperonin-containing tailless complex polypeptide subunit 6A (CCT6A) is a critical regulator and newly identified clinical biomarker of several cancers, while its correlation with the clinical characteristics and prognosis of cervical cancer patients is unclear. Therefore, this study aimed to explore this issue. Chaperonin-containing tailless complex polypeptide subunit 6A expression in tumor and tumor-adjacent tissues from 198 cervical cancer patients who underwent resection were detected by immunohistochemistry assay and reverse transcription-quantitative polymerase chain reaction. Besides, the clinicopathological features and survival data of cervical cancer patients were collected. Chaperonin-containing tailless complex polypeptide subunit 6A protein and mRNA levels were both increased in tumor tissues compared with tumor-adjacent tissues (both p < 0.001). Receiver operating characteristic curves showed that CCT6A protein (AUC: 0.774, 95% CI: 0.729-0.819) and mRNA levels (AUC: 0.904, 95% CI: 0.874-0.934) well discriminated tumor tissues from tumor-adjacent tissues. Besides, correlation analyses found that CCT6A protein and mRNA levels were positively correlated with lymph node metastasis and FIGO stage (all p < 0.05), apart from which CCT6A mRNA level was also positively associated with tumor size (p = 0.032). In addition, CCT6A protein and mRNA levels were negatively correlated with accumulating disease-free survival (both p < 0.05); meanwhile CCT6A mRNA level was negatively associated with accumulating overall survival as well (p = 0.010). Chaperonin-containing tailless complex polypeptide subunit 6A is elevated in tumor tissues, and its high expression associates with larger tumor size, lymph node metastasis, higher FIGO stage, and worse prognosis in cervical cancer patients.
Identifiants
pubmed: 34196992
doi: 10.1002/jcla.23793
pmc: PMC8373327
doi:
Substances chimiques
Biomarkers, Tumor
0
CCT6A protein, human
0
Chaperonin Containing TCP-1
EC 3.6.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23793Informations de copyright
© 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
Nat Struct Mol Biol. 2008 Dec;15(12):1255-62
pubmed: 19011634
Cancer Lett. 2020 Feb 28;471:88-102
pubmed: 31812696
Cancer Biomark. 2018;23(2):291-300
pubmed: 30198870
Medicine (Baltimore). 2021 Jan 29;100(4):e24484
pubmed: 33530265
Lancet. 2019 Jan 12;393(10167):169-182
pubmed: 30638582
J BUON. 2016 Mar-Apr;21(2):320-5
pubmed: 27273940
Dev Neurobiol. 2015 Sep;75(9):1033-48
pubmed: 25652596
World J Surg Oncol. 2020 Jul 6;18(1):156
pubmed: 32631353
Int J Med Sci. 2019 Jun 2;16(6):800-812
pubmed: 31337953
AJR Am J Roentgenol. 2020 May;214(5):1182-1195
pubmed: 32182097
Onco Targets Ther. 2020 Aug 12;13:8037-8047
pubmed: 32884290
Mol Med Rep. 2019 May;19(5):4344-4352
pubmed: 30942452
Molecules. 2020 Jan 06;25(1):
pubmed: 31935877
J Thorac Dis. 2018 Apr;10(4):2089-2099
pubmed: 29850112
Asian Pac J Cancer Prev. 2015;16(17):7401-7
pubmed: 26625735
Onco Targets Ther. 2019 Nov 29;12:10427-10439
pubmed: 31819524
Oncol Res Treat. 2016;39(9):501-6
pubmed: 27614953
Biomark Med. 2016 Jul;10(7):711-9
pubmed: 27347840
J Clin Invest. 2017 May 1;127(5):1725-1740
pubmed: 28375158